File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac

TitleThe Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac
Authors
KeywordsCoronaVac
COVID-19 vaccine
gut microbiota
vaccine
vaccine immunogenicity
Issue Date23-Feb-2024
PublisherMDPI
Citation
International Journal of Molecular Sciences, 2024, v. 25, n. 5 How to Cite?
Abstract

CoronaVac immunogenicity decreases with time, and we aimed to investigate whether gut microbiota associate with longer-term immunogenicity of CoronaVac. This was a prospective cohort study recruiting two-dose CoronaVac recipients from three centres in Hong Kong. We collected blood samples at baseline and day 180 after the first dose and used chemiluminescence immunoassay to test for neutralizing antibodies (NAbs) against the receptor-binding domain (RBD) of wild-type SARS-CoV-2 virus. We performed shotgun metagenomic sequencing performed on baseline stool samples. The primary outcome was the NAb seroconversion rate (seropositivity defined as NAb ≥ 15AU/mL) at day 180. Linear discriminant analysis [LDA] effect size analysis was used to identify putative bacterial species and metabolic pathways. A univariate logistic regression model was used to derive the odds ratio (OR) of seropositivity with bacterial species. Of 119 CoronaVac recipients (median age: 53.4 years [IQR: 47.8-61.3]; male: 39 [32.8%]), only 8 (6.7%) remained seropositive at 6 months after vaccination. Bacteroides uniformis (log10LDA score = 4.39) and Bacteroides eggerthii (log10LDA score = 3.89) were significantly enriched in seropositive than seronegative participants. Seropositivity was associated with B. eggerthii (OR: 5.73; 95% CI: 1.32-29.55; p = 0.022) and B. uniformis with borderline significance (OR: 3.27; 95% CI: 0.73-14.72; p = 0.110). Additionally, B. uniformis was positively correlated with most enriched metabolic pathways in seropositive vaccinees, including the superpathway of adenosine nucleotide de novo biosynthesis I (log10LDA score = 2.88) and II (log10LDA score = 2.91), as well as pathways related to vitamin B biosynthesis, all of which are known to promote immune functions. In conclusion, certain gut bacterial species (B. eggerthii and B. uniformis) and metabolic pathways were associated with longer-term CoronaVac immunogenicity.


Persistent Identifierhttp://hdl.handle.net/10722/342046
ISSN
2023 Impact Factor: 4.9
2023 SCImago Journal Rankings: 1.179
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNg, Ho-Yu-
dc.contributor.authorLiao, Yunshi-
dc.contributor.authorZhang, Ruiqi-
dc.contributor.authorChan, Kwok-Hung-
dc.contributor.authorTo, Wai-Pan-
dc.contributor.authorHui, Chun-Him-
dc.contributor.authorSeto, Wai Kay-
dc.contributor.authorLeung, Wai K-
dc.contributor.authorHung, Fan Ngai-
dc.contributor.authorLam, Tommy T Y-
dc.contributor.authorCheung, Ka Shing-
dc.date.accessioned2024-03-26T05:39:17Z-
dc.date.available2024-03-26T05:39:17Z-
dc.date.issued2024-02-23-
dc.identifier.citationInternational Journal of Molecular Sciences, 2024, v. 25, n. 5-
dc.identifier.issn1661-6596-
dc.identifier.urihttp://hdl.handle.net/10722/342046-
dc.description.abstract<p>CoronaVac immunogenicity decreases with time, and we aimed to investigate whether gut microbiota associate with longer-term immunogenicity of CoronaVac. This was a prospective cohort study recruiting two-dose CoronaVac recipients from three centres in Hong Kong. We collected blood samples at baseline and day 180 after the first dose and used chemiluminescence immunoassay to test for neutralizing antibodies (NAbs) against the receptor-binding domain (RBD) of wild-type SARS-CoV-2 virus. We performed shotgun metagenomic sequencing performed on baseline stool samples. The primary outcome was the NAb seroconversion rate (seropositivity defined as NAb ≥ 15AU/mL) at day 180. Linear discriminant analysis [LDA] effect size analysis was used to identify putative bacterial species and metabolic pathways. A univariate logistic regression model was used to derive the odds ratio (OR) of seropositivity with bacterial species. Of 119 CoronaVac recipients (median age: 53.4 years [IQR: 47.8-61.3]; male: 39 [32.8%]), only 8 (6.7%) remained seropositive at 6 months after vaccination. <em>Bacteroides uniformis</em> (log10LDA score = 4.39) and <em>Bacteroides eggerthii</em> (log10LDA score = 3.89) were significantly enriched in seropositive than seronegative participants. Seropositivity was associated with <em>B. eggerthii</em> (OR: 5.73; 95% CI: 1.32-29.55; <em>p</em> = 0.022) and <em>B. uniformis</em> with borderline significance (OR: 3.27; 95% CI: 0.73-14.72; <em>p</em> = 0.110). Additionally, <em>B. uniformis</em> was positively correlated with most enriched metabolic pathways in seropositive vaccinees, including the superpathway of adenosine nucleotide de novo biosynthesis I (log10LDA score = 2.88) and II (log10LDA score = 2.91), as well as pathways related to vitamin B biosynthesis, all of which are known to promote immune functions. In conclusion, certain gut bacterial species (<em>B. eggerthii</em> and <em>B. uniformis</em>) and metabolic pathways were associated with longer-term CoronaVac immunogenicity.<br></p>-
dc.languageeng-
dc.publisherMDPI-
dc.relation.ispartofInternational Journal of Molecular Sciences-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCoronaVac-
dc.subjectCOVID-19 vaccine-
dc.subjectgut microbiota-
dc.subjectvaccine-
dc.subjectvaccine immunogenicity-
dc.titleThe Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac-
dc.typeArticle-
dc.identifier.doi10.3390/ijms25052583-
dc.identifier.scopuseid_2-s2.0-85187684732-
dc.identifier.volume25-
dc.identifier.issue5-
dc.identifier.eissn1422-0067-
dc.identifier.isiWOS:001182884900001-
dc.identifier.issnl1422-0067-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats